Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
MimiVax, Inc. logo — Disrupting Cancer with Immunotherapy

MimiVax, Inc.

Disrupting Cancer with Immunotherapy

Founded 2012 United States Buffalo, United States 3 employees Series Unknown Total: $16.55M Biopharma, Biotechnology +1

General Information

Company Name MimiVax, Inc.
Founded Year 2012
Location United States Buffalo, United States +1
Founders / Decision Makers
Team member
Employees 3
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Series Unknown
Social

Get notified when MimiVax, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About MimiVax, Inc.

MimiVax, Inc. is a privately held, clinical-stage biotechnology company founded in 2012 with a vision to disrupt cancer through highly innovative immunotherapies. The company's lead immunotherapeutic vaccine, , has shown promise by completing a Phase 2a clinical trial in adults with newly diagnosed glioblastoma. Furthermore, MimiVax is actively pursuing additional indications through Phase 1 clinical trials in multiple myeloma in combination with REVLIMID® (lenalidomide), Phase 1 in Neuro-Endocrine Tumors (NET), and a Pilot Study in Pediatric High Grade Glioma, recurrent/relapsed Medulloblastoma, and DIPG. The recent Venture Round investment on 09 January 2024 has brought in new support from prominent investors such as Meda Angels, Varia Ventures, Brain Tumor Investment Fund, Sontag Family Trust. MimiVax's commitment to revolutionizing cancer treatment through immunotherapy presents a compelling opportunity for potential investors in the biopharma, biotechnology, and pharmaceutical sectors.

Taxonomy: Immunotherapy, Cancer treatment, Clinical-stage company, Immunotherapeutic vaccines, Targeted therapies, Survivin-targeting technology, Glioblastoma, Multiple myeloma, Neuro-Endocrine Tumors, Pediatric High Grade Glioma, Medulloblastoma, DIPG, Oncology, Pharmaceutical development

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• 4
Investor Investor Investor
•••• •••• 		09 Jan 2024
Series B •••••• - 10 Dec 2021
Non Equity Assistance •••••• - 12 Nov 2019
Venture Round •••••• - 25 Aug 2015

MimiVax, Inc. Alternatives & Competitors

MimiVax, Inc. vs
BioVaxys Technology Corp.
BioVaxys Technology Corp. Canada

Antiviral and Anticancer Vaccine Platforms Harnessing the Power of T-Cells

Post Ipo Equity
5 employees
Biopharma, Biotechnology
MimiVax, Inc. vs
Georgiamune Inc.
Georgiamune Inc. United States

Georgiamune is reprogramming immune signaling pathways to redirect the immune system to fight diseas...

Series A
30 employees
Biotechnology, Health Care
MimiVax, Inc. vs
MabVax Therapeutics, Inc.
MabVax Therapeutics, Inc. United States

MabVax Therapeutics (Nasdaq: MBVX) is a clinical-stage biotechnology company with a fully human anti...

Post Ipo Equity
4 employees
Biotechnology, Pharmaceutical

FAQ About MimiVax, Inc.

Disrupting Cancer with Immunotherapy
MimiVax, Inc. was founded in 2012.
MimiVax, Inc. is headquartered in Buffalo, United States.
MimiVax, Inc. operates in the following industries: Biopharma, Biotechnology, Pharmaceutical.
MimiVax, Inc. has approximately 3 employees.
MimiVax, Inc. has completed 4 funding rounds, raising a total of $16.55M. The latest funding stage is Series Unknown.
Top alternatives and competitors to MimiVax, Inc. include BioVaxys Technology Corp., Georgiamune Inc., MabVax Therapeutics, Inc., Barinthus Biotherapeutics, Adiposs. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MimiVax, Inc. and BioVaxys Technology Corp. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors MimiVax, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy